Cited 0 times in
Hypofractionated volumetric-modulated arc therapy for breast cancer: A propensity-score-weighted comparison of radiation-related toxicity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 금기창 | - |
dc.contributor.author | 김용배 | - |
dc.contributor.author | 서창옥 | - |
dc.contributor.author | 장지석 | - |
dc.contributor.author | 김나리 | - |
dc.date.accessioned | 2021-12-28T17:15:35Z | - |
dc.date.available | 2021-12-28T17:15:35Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187013 | - |
dc.description.abstract | We assessed the clinical benefit of combining volumetric-modulated arc therapy (VMAT) and hypofractionated radiotherapy (HF-RT) considering the incidence of radiation-related toxicities. After a retrospective review for breast cancer patients treated with adjuvant RT between 2005 and 2017, a total of 4209 patients treated with three-dimensional conventional fractionation (CF-3D, 50.4 Gy/28 fractions) and 1540 patients treated with HF-RT (768 received HF-3D; 772, HF-VMAT; 40 Gy/15 fractions) were included. A total of 2229 patients (38.8%) received regional node irradiation (RNI): 1642 (39.0%), 167 (21.7%) and 420 (54.4%) received RNI via CF-3D, HF-3D and HF-VMAT, respectively. Acute/subacute and late toxicities were evaluated. Propensity scores were calculated via logistic regression. Grade 2+ acute/subacute toxicities was the highest in CF-3D group (15.0%, 2.6% and 1.6% in CF-3D, HF-3D and HF-VMAT, respectively; P < .001). HF-VMAT reduced Grade 2+ acute/subacute toxicities significantly compared to CF-3D (odds ratio [OR] 0.11, P < .001) and HF-3D (OR 0.45, P = .010). The 3-year cumulative rate of late toxicities was 18.0% (20.1%, 10.9% and 13.4% in CF-3D, HF-3D and HF-VMAT, respectively; P < .001). On sensitivity analysis, the benefit of HF-VMAT was high in the RNI group. Acute and late toxicities were fewer after HF-VMAT than after HF-3D or CF-3D, especially in women who underwent RNI. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Hypofractionated volumetric-modulated arc therapy for breast cancer: A propensity-score-weighted comparison of radiation-related toxicity | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Nalee Kim | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Chirag Shah | - |
dc.contributor.googleauthor | Hyejung Shin | - |
dc.contributor.googleauthor | Ki Chang Keum | - |
dc.contributor.googleauthor | Chang-Ok Suh | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.identifier.doi | 10.1002/ijc.33525 | - |
dc.contributor.localId | A00272 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A01919 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J01092 | - |
dc.identifier.eissn | 1097-0215 | - |
dc.identifier.pmid | 33600612 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/ijc.33525 | - |
dc.subject.keyword | breast cancer | - |
dc.subject.keyword | hypofractionated radiotherapy | - |
dc.subject.keyword | radiotherapy dose fractionation | - |
dc.subject.keyword | toxicity | - |
dc.subject.keyword | volumetric-modulated arc therapy | - |
dc.contributor.alternativeName | Keum, Ki Chang | - |
dc.contributor.affiliatedAuthor | 금기창 | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.contributor.affiliatedAuthor | 서창옥 | - |
dc.contributor.affiliatedAuthor | 장지석 | - |
dc.citation.volume | 149 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 149 | - |
dc.citation.endPage | 157 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CANCER, Vol.149(1) : 149-157, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.